You can buy or sell Roche and other stocks, options, ETFs, and crypto commission-free!
Roche Holding AG operates as a research healthcare company. It operates through the following segments: Diagnostics and Pharmaceuticals. Read More The pharmaceutical segment refers to development of medicines in the field of oncology, immunology, ophthalmology, infectious diseases and neuroscience. The diagnostic segment refers to diagnosis of diseases through an in vitro diagnostics process. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland. RHHBY is listed on the OTCQX International Premier market tier. OTC market data is provided by OTC Markets Group, Inc (otcmarkets.com).
Basel, Basel-Stadt (Basle Town)
52 Week High
52 Week Low
Yahoo FinanceMay 23
Synlogic Enters Cancer Collaboration with Roche
Synlogic, Inc. SYBX announced that it has entered a new collaboration with large pharma company, Roche RHHBY. Synlogic will develop its Synthetic Biotic medicine, SYNB1891, in combination with Roche’s PD-L1 inhibitor, Tecentriq (atezolizumab), as a treatment for advanced solid tumors. SYNB1891 is a pre-clinical stage candidate. Synlogic is expected to file an investigational new drug (“IND”) application with the FDA in the second half of 2019to initiate a phase I study to evaluate SYNB1891 as monotherapy a...
Seeking AlphaMay 22
Synlogic teams up with Roche in potential combo therapy for solid tumors
Synlogic (NASDAQ:SYBX) will collaborate with Roche (OTCQX:RHHBY) on clinical studies evaluating the combination of SYNB1891, a STING agonist, and Tecentriq (atezolizumab) in patients with advanced solid tumors.
Seeking AlphaMay 16